1. Market Research
  2. > Healthcare Market Trends
  3. > Accountable Care Organizations: What Impact on Pharma?

Accountable Care Organizations: What Impact on Pharma?

  • July 2015
  • -
  • Datamonitor Healthcare
  • -
  • 50 pages

Summary

Table of Contents

Search Inside

The Affordable Care Act (ACA) passed in 2010 was the catalyst to a range of changes to the US healthcare system. Among the most important of these changes was how healthcare is paid for, with a number of ACA measures aimed at moving away from a fee-for-service reimbursement to payment of providers according to outcomes and quality of care. This shift from volume- to value-based reimbursement is captured most prominently in the establishment of Accountable Care Organizations (ACOs). ACOs are groups of doctors, hospitals, and other healthcare providers that share the risk, responsibility, and reward associated with delivering more cost-effective, higher-quality, and better-coordinated care. There are now over 700 ACOs in the US, spanning both the publicly funded Medicare and Medicaid, as well as the private sector.

The impact of this growing ACO movement on the pharma industry has so far been limited, but this is changing. Pharma firms have opportunities to engage with these restructured providers in new ways, including by helping to influence and set treatment best practice across different therapy areas, providing pharmacoeconomic and outcomes data, and potentially supporting a more prominent role for pharmacists within ACOs.

This report addresses the following questions:
- What are ACOs and how do they differ from other players in the US healthcare system?
- How is the role of medication management evolving within ACOs?
- What impact have ACOs had on the pharmaceutical market so far and how will that change in the future?
- What strategies for pharma-ACO engagement will be most successful?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...

Healthcare IT Market by Product (EHR, RIS, PACS, VNA, CPOE, HIE, Telehealth, Healthcare Analytics, Population Health Management, Supply Chain Management, CRM, Fraud Management, Claims Management) End User (Provider, Payer) - Global Forecast to 2021

Healthcare IT Market by Product (EHR, RIS, PACS, VNA, CPOE, HIE, Telehealth, Healthcare Analytics, Population Health Management, Supply Chain Management, CRM, Fraud Management, Claims Management) End User (Provider, Payer) - Global Forecast to 2021

  • $ 8150
  • Industry report
  • March 2017
  • by MarketsandMarkets

The global healthcare IT market is expected to grow at a CAGR of 15.9% from 2016 to 2021 and reach USD 280.25 billion. Growing need to manage regulatory compliance through healthcare IT solutions, government ...

Asia-Pacific Bronchoscopes Market Outlook to 2023

Asia-Pacific Bronchoscopes Market Outlook to 2023

  • $ 5995
  • Industry report
  • April 2017
  • by GlobalData

Asia-Pacific Bronchoscopes Market Outlook to 2023 Summary GlobalData’s new report, "Asia-Pacific Bronchoscopes Market Outlook to 2023", provides key market data on the Asia-Pacific Bronchoscopes market. ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.